Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antibody to a naturally-occurring sugar chain in colon inhibits inflammatory bowel disease

10.10.2005


Ensemble of usual sugars offers clues to controlling inflammation



A collaboration led by the Burnham Institute for Medical Research has found that an antibody which binds to an unusual sugar molecule residing in the gut halts the inflammation seen in Crohn’s disease and other intestinal inflammations. The antibody could prove to be a promising drug target for these common chronic intestinal disorders.

Professor Hudson Freeze, Ph.D., director of Burnham’s glycobiology and carbohydrate chemistry program, together with staff scientist Geetha Srikrishna, Ph.D., and other colleagues found that a naturally "tweaked" sugar chain normally present on white blood cells and intestinal cells plays a role in inflammation. In addition, the team found that an antibody produced in reaction to the sugar’s presence curbed intestinal inflammation induced in mice. These findings will be published in the October 15th edition of Journal of Immunology.


"We looked at a number of sugar-binding molecules that may have had a role in inflammation," said Freeze. "One of the sugar chains elicited an antibody response, so we wondered whether the antibody would be able to block inflammation in mice. If so, this could have implications for inflammatory bowel disease, Crohn’s, and also might help combat other autoimmune inflammatory diseases, like arthritis."

The team identified a modified version of very common sugars known as N-linked glycans, which are found on the surface of white blood cells, as well as normal colon cells. These sugars are also found in colon tissue of patients suffering from Crohn’s disease.

The antibody was tested in a mouse model for Crohn’s disease created by transferring white blood cells with the capacity to induce severe intestinal inflammation into mice with compromised immune systems. "When administered 10 days after disease onset, the antibody was able to reverse early symptoms of inflammation and halt further progress of disease," said Srikrishna. The antibody also reduced the accumulation of white blood cells armed to fight disease and inhibited the expression of cellular messengers (cytokines) typically seen in inflammation.

"There are a large number of signaling molecules that are activated in inflammation," said Freeze. "Antibodies against these sugar chain molecules, however, appear to curb inflammation before cytokines associated with inflammation, like NF-kB and TNF, are activated. The sugar chain must be used at an earlier stage, but in a more specific manner."

The sugar chain’s specificity could be crucial to developing treatments for Crohn’s and other inflammatory disorders. The body’s inflammation response usually is a healthy reaction to harmful foreign agents; inflammation disposes of pathogens before they cause disease. Crohn’s disease and other inflammatory bowel diseases, generally known as auto-immune disorders, are a result of the body’s immune system overreacting to non-existent pathogens, causing the body to attack its own tissues. The optimal treatment would inhibit excessive inflammation linked with disease, leaving normal immune function unaffected.

The antibody, Freeze suggests, could prove to be an effective remedy for autoimmune disorders if it can act specifically on hyperactive inflammation, while preserving the immune system. RemicadeTM, an antibody-based drug currently used for Crohn’s, works by inhibiting the cytokines that are summoned into action at a later phase of these diseases.

"Our next step is to identify the molecular players in the body’s early inflammatory response in the intestine," said Freeze. The team is focusing on one particular molecule called RAGE (short for Receptor for Advanced Glycation End Products), which has been implicated in the pathology of inflammation, as well as cancer, diabetes and Alzheimer’s disease. They are also determining the exact molecular structure of the tweaked sugar chain, and will determine what other molecules and receptors may interact with it.

Eventually, the researchers hope that they will have enough promising information to merit a clinical trial to test the antibody’s effectiveness. "Our antibody was developed for use in mice. We need to "humanize" it, make the antibody suitable for human consumption. This could take some development, but the results could be very beneficial," Freeze said.

Freeze’s and Srikrishna’s colleagues included Professor Mitchell Kronenberg, Olga Turovskaya and Raziya Shaikh of the La Jolla Institute for Allergy and Immunology, Robbin Newlin of Burnham, Dirk Foell of the University of Muenster, Germany, and Simon Murch of the University of Warwick, England. The team’s research is supported by grants from the Broad Medical Research Program of The Eli and Edythe L. Broad Foundation and the National Institutes of Health.

Nancy Beddingfield | EurekAlert!
Further information:
http://www.burnham.org

More articles from Life Sciences:

nachricht The secret sulfate code that lets the bad Tau in
16.07.2018 | American Society for Biochemistry and Molecular Biology

nachricht Colorectal cancer risk factors decrypted
16.07.2018 | Max-Planck-Institut für Stoffwechselforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Nano-kirigami: 'Paper-cut' provides model for 3D intelligent nanofabrication

16.07.2018 | Physics and Astronomy

New players, standardization and digitalization for more rail freight transport

16.07.2018 | Transportation and Logistics

Researchers discover natural product that could lead to new class of commercial herbicide

16.07.2018 | Agricultural and Forestry Science

VideoLinks
Science & Research
Overview of more VideoLinks >>>